Table 1.

Baseline Characteristics by Treatment Group

Ibuprofen n = 111 (100%)Placebo n = 119 (100%)
Demographic characteristics
Female gender41 (37%)49 (41%)
Age at study entry1-a 1.9 (1.4–2.4)1.9 (1.4–2.7)
First-degree family history of febrile seizures* 27 (24%)32 (27%)
Family history of any seizures44 (40%)49 (41%)
Day-care attendance39 (35%)49 (41%)
First born70 (63%)59 (50%)
Caucasian origin67 (60%)78 (66%)
Immunization completed1-b 85 (77%)88 (74%)
Initial seizure characteristics
Age at onset1-a 1.4 (1.1–1.9)1.5 (1.0–2.1)
FSE1-c 8 (7%)12 (10%)
Focal type1-d 16 (14%)10 (8%)
Multiple type1-e,* 47 (42%)40 (34%)
Rectal temperature below 40.0°C* 55 (50%)66 (56%)
Previous recurrent febrile seizures
Previous recurrent febrile seizures* 39 (35%)45 (38%)
Time lapse between last seizure and study entry1-a 0.10 (0.05–0.21)0.07 (0.04–0.18)
Number of risk factors
166 (60%)66 (56%)
233 (30%)44 (37%)
≥312 (11%)9 (8%)
  • F1-a In years, median (25th–75th percentiles).

  • F1-b According to the national guidelines for immunization in the Netherlands.

  • F1-c Febrile status epilepticus, seizure duration ≥30 min.

  • F1-d Focal onset of the seizure or postictal Todd's paresis.

  • F1-e Seizure recurrence within 24 hours.

  • * Risk factor for febrile seizure recurrence discussed in “Patients”.